PRECISE MRI Scoring Predicts Histological Progression in Prostate Cancer Surveillance

Optimizing Active Surveillance for Prostate Cancer

Prostate cancer remains the most frequently diagnosed malignancy among men in the United States, with incidence rates increasing by 2% to 3% annually in recent years [1, 2]. For patients with low-risk disease, active surveillance (a management approach involving regular monitoring rather than immediate surgery or radiation) has become the preferred strategy to avoid the morbidity associated with definitive treatment [3, 4]. However, current protocols often rely on serial confirmatory biopsies, which carry risks of infection and discomfort, yet approximately 20% of these procedures reveal disease upgrading that necessitates a change in management [5, 4]. While multiparametric MRI is increasingly integrated into these surveillance pathways, its reliability as a standalone tool for ruling out progression has remained a subject of clinical debate [6, 7]. A multicenter validation study now examines how a standardized radiological scoring system for sequential imaging might refine these monitoring protocols, potentially allowing clinicians to safely defer invasive biopsies in select patients.

Standardizing Radiological Assessment in Serial Imaging

The Prostate Cancer Radiological Estimation of Change in Sequential Evaluation (PRECISE) recommendations provide a standardized framework for assessing radiological change in serial MRI during active surveillance. This 5-point scoring system categorizes imaging findings to guide clinical decision-making based on the evolution of visible lesions. Specifically, PRECISE scores of 1 to 2 indicate radiological regression, while a PRECISE score of 3 indicates radiological stability. Conversely, PRECISE scores of 4 to 5 indicate radiological progression, signaling a potential need for histological re-evaluation or a shift toward active treatment. By providing these clear definitions, the system aims to reduce inter-observer variability among radiologists. To validate the predictive utility of these scores, researchers conducted a retrospective study collecting data from 22 international centers between December 2005 and July 2022. Study entry required participants to have at least two MRI scans (a baseline and a follow-up) and at least two biopsies, with the follow-up biopsy occurring after the second MRI. This longitudinal approach allowed the authors to correlate changes in radiological scores directly with tissue-based evidence of disease progression or stability.

Longitudinal Outcomes and Histological Progression Rates

The multicenter study evaluated a total of 1667 patients to determine the predictive accuracy of the PRECISE scoring system. These participants were monitored over a median follow-up period of 4 years (interquartile range: 2.1 to 6.3 years). This observation window provided sufficient time to capture the natural history of low-risk prostate cancer and the transition from stable disease to histological progression. A critical component of the analysis focused on the correlation between imaging and tissue samples. A total of 1248 patients (75%) underwent a diagnostic sequence that included two MRI scans followed by an immediate subsequent biopsy, allowing for a direct comparison between the radiological score and the current pathological state of the malignancy. Among the patients who received an immediate biopsy, 300 individuals (24%) demonstrated biopsy progression to Grade Group 2 or higher (a contemporary histological classification indicating the presence of intermediate-risk disease patterns). Furthermore, 77 patients (6%) progressed to Grade Group 3 or higher, a threshold that often triggers a shift from active surveillance to definitive treatment such as surgery or radiation therapy. These findings quantify the risk of upgrading in an active surveillance population and establish the baseline rates of progression against which the PRECISE scoring system was validated.

Predictive Value and Clinical Implementation

The study demonstrated that radiological changes captured by the PRECISE system are highly indicative of pathological upgrading. Specifically, patients with PRECISE scores of 4 or 5 had 4.53-fold increased odds of biopsy progression compared to those with PRECISE scores of 1 to 3 (95% confidence interval: 3.37 to 6.12; p < 0.001). This strong correlation suggests that the scoring system effectively mirrors the biological activity of the tumor, providing clinicians with a validated metric to assess risk during the surveillance period. When evaluating the diagnostic performance of the system using a PRECISE score of 4 or higher as the threshold for performing follow-up biopsies, the researchers reported an overall sensitivity of 57% and a specificity of 79% for the first follow-up scan. The positive predictive value was 46%, while the negative predictive value reached 85%. For practicing urologists and oncologists, this high negative predictive value is the most clinically actionable finding: it indicates that 85% of patients with stable or regressing MRI findings truly do not have histological progression. Consequently, the PRECISE system can identify patients who require timely re-biopsy or treatment, while safely reducing the frequency of repeat biopsies for patients who demonstrate stable MRI findings alongside stable prostate-specific antigen (PSA) kinetics. By integrating radiological stability with biochemical markers, physicians can better personalize surveillance schedules, minimizing the morbidity associated with serial biopsies in men with indolent disease.

References

1. Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA A Cancer Journal for Clinicians. 2024. doi:10.3322/caac.21820

2. Miller KD, Nogueira L, Mariotto AB, et al. Cancer treatment and survivorship statistics, 2019. CA A Cancer Journal for Clinicians. 2019. doi:10.3322/caac.21565

3. Kinsella N, Helleman J, Bruinsma S, et al. Active surveillance for prostate cancer: a systematic review of contemporary worldwide practices.. Translational andrology and urology. 2018. doi:10.21037/tau.2017.12.24

4. Curtain BMM, Daly K, Calpin G, et al. Reclassification of prostate cancer on first confirmatory prostate biopsy in men under active surveillance: A systematic review and meta-analysis.. Central European journal of urology. 2025. doi:10.5173/ceju.2025.0011

5. Schoots IG, Nieboer D, Giganti F, Moore CM, Bangma CH, Roobol MJ. Is magnetic resonance imaging-targeted biopsy a useful addition to systematic confirmatory biopsy in men on active surveillance for low-risk prostate cancer? A systematic review and meta-analysis.. BJU international. 2018. doi:10.1111/bju.14358

6. Rajwa P, Pradere B, Quhal F, et al. Reliability of Serial Prostate Magnetic Resonance Imaging to Detect Prostate Cancer Progression During Active Surveillance: A Systematic Review and Meta-analysis.. European urology. 2021. doi:10.1016/j.eururo.2021.05.001

7. Cantiello F, Russo GI, Kaufmann S, et al. Role of multiparametric magnetic resonance imaging for patients under active surveillance for prostate cancer: a systematic review with diagnostic meta-analysis.. Prostate cancer and prostatic diseases. 2019. doi:10.1038/s41391-018-0113-2